Ligand Pharmaceuticals Incorporated (LGNZZ)

Overview

Ligand Pharmaceuticals Incorporated is a pioneering biopharmaceutical company that commits to the development and licensing of innovative biopharmaceutical assets on a global scale. Since its inception in 1987, Ligand has built a remarkable portfolio of products and formed strategic alliances with industry leaders such as Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Operating from its headquarters in Jupiter, Florida, the company not only focuses on the discovery of novel therapies but also markets Captisol materials, a technology designed to improve the solubility and stability of drugs.

Products and Services

• Kyprolis & Evomela - Utilized in the treatment of multiple myeloma, a type of cancer affecting plasma cells in the bone marrow.
• Rylaze - A recombinant erwinia asparaginase designed for treating acute lymphoblastic leukemia or lymphoblastic lymphoma in both adults and pediatric patients.
• Filspari - Currently under development, this dual endothelin and angiotensin II receptor antagonist is targeted for rare kidney diseases and serves as a non-immunosuppressive treatment for immunoglobulin A nephropathy.
• Teriparatide injection - A product indicated for the management of osteoporosis, helping to strengthen bone.
• Vaxneuvance & Pneumosil - Vaccines aimed at preventing invasive disease caused by Streptococcus pneumoniae serotypes, with Pneumosil specifically targeting pneumococcal pneumonia among children.
• TZIELD - A CD3-directed antibody intended to delay the onset of Stage 3 type 1 diabetes (T1D) in individuals aged 8 years and older with Stage 2 T1D.
• Nexterone - A captisol-enabled formulation of amiodarone, catering to patients requiring this antiarrhythmic medication in a more tolerable form.
• Zulresso - A captisol-enabled formulation of brexanolone for treating postpartum depression, offering a new treatment avenue for affected women.
• Veklury - An antiviral treatment for patients with moderate or severe COVID-19, contributing to the expansive arsenal against the pandemic.
• Noxafil-IV - A captisol-enabled formulation of posaconazole for IV use, aimed at preventing fungal infections in immunocompromised patients.
• Duavee - Addressing the treatment of post-menopausal symptoms in women, providing a combination of estrogen and bazedoxifene.
• Exemptia, Vivitra, Bryxta, and Zybev - A diverse range of treatments targeting autoimmune diseases, breast cancer, and various other indications, showcasing Ligand’s broad impact on healthcare.